Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo‐Youn Oh, Juan W. Valle, Howard A. Burris et al.|NEJM Evidence|2022Cited by 1.1k
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Aiwu Ruth He et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylaseElena Di Gennaro, Alfredo Budillon, Geny Piro et al.|British Journal of Cancer|2010Cited by 49
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologistsMargaret Ottaviano, Vincenzo Montesarchio, Marcello Curvietto et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 19
Abstract 3721: Critical role of Bevacizumab schedule in combination with chemo-radiotherapy in neo-adjuvant treatment of rectal cancer: Circulating endothelial cells and FDG-PET as markers for early predictionAntonio Avallone, Alfredo Budillon, Elena Di Gennaro et al.|Cancer Research|2010Cited by 0